Cepheid Logo
Request Info
Location / Language

{{headingText}}

{{paragraphText}}

{{continueBtnLabel}}
{{initials}}
Main Menu
Location / Language

{{headingText}}

{{paragraphText}}

{{continueBtnLabel}}

Request Info
Request Info

Xpert® vanA

Order & Support
Van A computer generated depiction.
Rapid VRE screening for active outbreak prevention and control in around 48 minutes

The Need

an ill woman listens to a physician
  • Vancomycin Resistant Enterococci (VRE) are a growing public health threat and pose a risk to patient safety in healthcare facilities1
  • In healthcare settings, colonized patients and environmental contamination contribute to VRE spread1
  • High-risk patients colonized with VRE have 24 times increased infection risk2
  • Infections caused by VRE are associated with high mortality3
  • VRE has an impact on patient length-of-stay, and in turn, hospitalization costs3
1 Levitus M, et al. Vancomycin-Resistant Enterococci. StatPearls July 17, 2023. https://www.ncbi.nlm.nih.gov/books/NBK513233/?report=reader#_NBK513233_pubdet. Accessed December 11, 2023

2 Alevizakos M, et al. Colonization with vancomycin-resistant enterococci and risk for bloodstream infection among patients with malignancy: a systematic review and meta-analysis. Open Forum Infect Dis. 2016 Dec;4(1):ofw246.

3 Eichel V,M, et al. Epidemiology and outcomes of vancomycin-resistant enterococcus infections: a systematic review and meta-analysis. Journal of Hospital Infection 141 (2023) 119e128

The Solution

a male and a female researchers scanning cepheid test cartridges
  • The Xpert vanA test is a rapid molecular detection of the vanA gene associated with VRE colonization risk to aid in the recognition, prevention, and control of vancomycin-resistant organisms that colonize patients in healthcare settings
  • Fast, active screening of high-risk patients to support infection control measures in healthcare settings4
4 Babady N,E, et al. Performance Characteristics of the Cepheid Xpert vanA Assay for Rapid Identification of Patients at High Risk for Carriage of Vancomycin-Resistant Enterococci. Journal of Clinical Microbiology, November 2012 Volume 50 Number 11 p. 3659–3663

The Impact

a smiling female doctor attends an elderly woman
Published studies have reported improved infection control workflows following implementation of rapid molecular screening5
  • 93% reduction of turnaround time from 70.5h with chromogenic agar culture to 4.6h
  • High negative predictive value allows for better management of non-colonized patients
  • Associated with a reduction in the number of identified contact patients
Published studies have reported reductions in isolation days following implementation of rapid vanA screening6:
  • 141 saved isolation days and 292 saved transmission risk days
5 Birgand G, et al. Lucet JC. Rapid detection of glycopeptide-resistant enterococci: impact on decision-making and costs. Antimicrobial Resistant and Infection Control. 2013 Nov 2:30.

6 Holzknecht BJ, Hansen DS, Nielsen L, Kailow A, Jarløv JO. Screening for vancomycin-resistant enterococci with Xpert® vanA/vanB: diagnostic accuracy and impact on infection control decision making. New Microbes New Infect. 2017 Jan 12;16:54-59

* 1€=1.09$, conversion rate December 15th 2023

Connect To Better Outcomes

Request Info

Insights

Get More Insights